Merck and Co., Inc. (MRK) |
| 148.26 -1.28 (-0.86%) 08-28 16:00 |
| Open: | 146.72 |
| High: | 149.0078 |
| Low: | 145.75 |
| Volume: | 7,694,759 |
| Market Cap: | 366,176(M) |
| PE Ratio: | 46.19 |
| Exchange: | New York Stock Exchange |
| Industry: | Drug Manufacturers - General |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 183.27 |
| Resistance 1: | 156.91 |
| Pivot price: | 143.24 |
| Support 1: | 137.94 |
| Support 2: | 126.22 |
| 52w High: | 156.92 |
| 52w Low: | 77.58 |
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
| EPS | 1.250 |
| Book Value | 16.990 |
| PEG Ratio | 14.56 |
| Gross Profit | 20.457 |
| Profit Margin (%) | 4.77 |
| Operating Margin (%) | -0.24 |
| Return on Assets (ttm) | 11.9 |
| Return on Equity (ttm) | 7.0 |
Sat, 29 Aug 2026
New Mexico Educational Retirement Board Purchases 8,900 Shares of Merck & Co., Inc. $MRK - MarketBeat
Sat, 29 Aug 2026
Royal London Asset Management Ltd. Has $383.83 Million Stake in Merck & Co., Inc. $MRK - MarketBeat
Sat, 29 Aug 2026
Merck & Co., Inc. $MRK is Wellington Management Group LLP's 8th Largest Position - MarketBeat
Sat, 29 Aug 2026
Van ECK Associates Corp Sells 422,266 Shares of Merck & Co., Inc. $MRK - MarketBeat
Sat, 29 Aug 2026
Ferguson Wellman Capital Management Inc. Sells 9,312 Shares of Merck & Co., Inc. $MRK - MarketBeat
Sat, 29 Aug 2026
Braun Stacey Associates Inc. Has $35.07 Million Stock Position in Merck & Co., Inc. $MRK - MarketBeat
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |